UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000011988 |
|---|---|
| Receipt number | R000014009 |
| Scientific Title | Prevention of Contrast Induced Nephropathy after Endovascular Therapy combined with Carbon Dioxide-digital subtraction angiography in Patients With Ilio-Femoropopliteal artery diseases |
| Date of disclosure of the study information | 2013/10/08 |
| Last modified on | 2018/10/12 09:21:50 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prevention of Contrast Induced Nephropathy after Endovascular Therapy
combined with Carbon Dioxide-digital subtraction angiography in Patients
With Ilio-Femoropopliteal artery diseases
Acronym
CineCD
Scientific Title
Prevention of Contrast Induced Nephropathy after Endovascular Therapy
combined with Carbon Dioxide-digital subtraction angiography in Patients
With Ilio-Femoropopliteal artery diseases
Scientific Title:Acronym
CineCD
Region
| Japan |
Condition
Condition
peripheral artery disease
Classification by specialty
| Cardiology | Nephrology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To clarify the Prevention of Contrast Induced Nephropathy after Endovascular
Therapy combined with Carbon Dioxide-digital subtraction angiography(DSA) in
Patients With Ilio-Femoropopliteal artery diseasese.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Incidence of Contrast Induced Nephropathy
Key secondary outcomes
1)Safety of Endovascular Therapy with Carbon Dioxide-digital subtraction
angiography(DSA)
2)Comparison of ABI change after Endovascular Therapy
3)volume of contrast media, injection volume of Carbon Dioxide, Procedure
time, Endovascular Therapy related complication
4)comparison of final angiography in Endovascular Therapy
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Single blind -participants are blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Treatment
Type of intervention
| Device,equipment | Maneuver | Other |
Interventions/Control_1
Randomized Control arm With 60>eGFR>or=30 mL/min/1.73 m2: contrast
media-digital subtraction angiography
Interventions/Control_2
Randomized CO2 usage arm With 60>eGFR>or=30 mL/min/1.73 m2: contrast media
combined with Carbon Dioxide digital subtraction angiography
Interventions/Control_3
intervention CO2 usage arm with eGFR<30 mL/min/1.73 m2: contrast media
combined with Carbon Dioxide digital subtraction angiography
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
PAD patient recommended endovascular therapy in Patients With
Ilio-Femoropopliteal artery diseases and
estimated Glomerular Filtration Rate is less than 60ml/min./1.73m2.
not exclusion criteria patient.
patients with agreement for this study.
Key exclusion criteria
1)Life expectancy 6 months.
2)without regular dialysis
3)under 30years old
4)inappropriate patient determined from study director.
5)patient unavailable of anti platelet agents and anticoagulant.
6)Allergy of contrast agents.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Michiaki Higasitani |
Organization
Sakakibara Heart Institute
Division name
Department of Cardiology
Zip code
Address
3-16-1 Asahi-cyo Futyu-shi Tokyo
TEL
042-314-3111
mhigashi@shi.heart.or.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Clinical Trials Support Office |
Organization
Sakakibara Heart Institute
Division name
Clinical Trials Support Office
Zip code
Address
3-16-1 Asahi-cyo Futyu-shi Tokyo
TEL
042-314-3111
Homepage URL
tikenjim@shi.heart.or.jp
Sponsor or person
Institute
Sakakibara Heart Institute
Institute
Department
Personal name
Funding Source
Organization
Japan Research Promotion Society for Cardiovascular Disease
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 10 | Month | 08 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 10 | Month | 07 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 10 | Month | 07 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 10 | Month | 08 | Day |
Last modified on
| 2018 | Year | 10 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014009
